Saxenda® Frenzy: Opinions of an Endocrine and Metabolism Specialist / 임상당뇨병
Journal of Korean Diabetes
; : 63-66, 2019.
Article
en Ko
| WPRIM
| ID: wpr-761483
Biblioteca responsable:
WPRO
ABSTRACT
Globally, the problem of obesity is increasing, and the prevalence of obesity in Korea is also rising rapidly. Obesity is a risk factor for cardiometabolic diseases including type 2 diabetes mellitus, hypertension, cardiovascular disease, and some types of cancer. Therefore, prevention of various metabolic diseases or symptom relief through effective treatment of obesity is a very important problem. According to the obesity guidelines of the Obesity Society of Korea in 2018, obesity medication is recommended for patients with a body mass index (BMI) of 30 kg/m² or more or a BMI of 27 kg/m² or more, and one or more obesity accompanying diseases (type 2 diabetes, hypertension, dyslipidemia). In this case, it is recommended that the basic treatment for obesity (diet, exercise, and behavior therapy) should be performed in parallel with Saxenda® treatment. The glucagon-like peptide 1 analogue, Saxenda®, has been validated as a long-term effective and safe treatment for obesity, and is expected to be a promising drug for the treatment of obesity and the prevention of pre-diabetes in the future. However, in Korea, where non-standard obesity treatments are widely practiced, it is necessary to improve the health of obese patients by being treated with Saxenda® along with diet, exercise and behavior therapy.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Especialización
/
Terapia Conductista
/
Enfermedades Cardiovasculares
/
Índice de Masa Corporal
/
Prevalencia
/
Factores de Riesgo
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Dieta
/
Péptido 1 Similar al Glucagón
Tipo de estudio:
Etiology_studies
/
Guideline
/
Prevalence_studies
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Ko
Revista:
Journal of Korean Diabetes
Año:
2019
Tipo del documento:
Article